Selected Publications

Papamichael K, Vajravelu R, Cheifetz AS, Osterman MT: Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease. Digestive Diseases and Sciences 2018 Notes: In press.

Lewis JD, Scott F, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Chen L, Yun Huifeng, Xie F, Curtis JR: Reduced mortality rates with anti-tumor necrosis factor alpha directed therapy when compared to prolonged corticosteroid therapy for inflammatory bowel disease. Gastroenterology 2017 Notes: Oral presentation at annual Digestive Diseases Week meeting May 2017.

Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology 2017 Notes: In press.

Papamichael K, Chachu KA, Vajravelu R, Vaughn BP, Ni J, Cheifetz AS, Osterman MT: Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared to reactive monitoring of serum concentrations of infliximab. Clinical Gastroenterology and Hepatology 15: 1580-8, 2017.

Cross RK, Osterman MT, Panaccione R, Afzali A, Song X, Shi N, Ding Y, Wang A: The Incidence of Cardiovascular Events in Patients with Crohn's Disease Treated with Vedolizumab and Anti-TNF Therapies. Gastroenterology 2017 Notes: Poster presentation for annual Digestive Diseases Week meeting, Chicago IL, May 2017.

Osterman MT, Lichtenstein GR: Infliximab vs. Adalimumab for UC: Is There a Difference? Clinical Gastroenterology and Hepatology 15: 1197-9, 2017.

Papamichael, Chachu KA, Vajravelu R, Vaughn B, Ni J, Osterman MT, Cheifetz AS: Proactive compared to reactive therapeutic drug monitoring of infliximab is associated with less IBD-related surgery and hospitalization. Gastroenterology 2017 Notes: Poster presentation at annual Digestive Diseases Week meeting, Chicago IL, May 2017.

Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT: Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis Alimentary Pharmacology and Therapeutics 2017 Notes: In press.

Papamichael K, Osterman MT, Cheifetz AS: Reply. Clinical Gastroenterology and Hepatology 15: 1638-9, 2017.

Papamichael, Chachu KA, Vajravelu R, Vaughn B, Ni J, Osterman MT, Cheifetz AS: Proactive versus reactive therapeutic drug monitoring of infliximab in inflammatory bowel disease. Gastroenterology 2017 Notes: Poster presentation at annual Digestive Diseases Week meeting, Chicago IL, May 2017.